Síguenos en Twitter     Síguenos en Facebook     Síguenos en YouTube     Siguenos en Linkedin     Correo Grupsagessa     Gmail     Dropbox     Instagram     Google Drive     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon     StumbleUpon

SOBRE EL AUTOR **

My photo
FACP. Colegio de médicos de Tarragona Nº 4305520 / fgcapriles@gmail.com

WORLD EMERGENCY MEDICINE SOCIETIES & RELATED

Search

Content:

Monday, March 1, 2021

Haloperidol vs Ondasentron for CHS

EM Ottawa - By Hans Rosenberg - March 01, 2021
“Question and Methods: Randomized control trial in which cannabis users with active emesis received either haloperidol (0.05mg/kg or 0.1 mg/kg IV) or ondansetron 8mg IV for symptomatic relief.
Findings: 33 patients were enrolled and randomized, and for the primary outcome haloperidol (either dose) was superior to ondansetron [Difference 2.3 cm (95% confidence 0.6-4.0cm); P=0.01].
Limitations: This study had several limitations including complex design, enrollment difficulties, unplanned interim analyses, and unclear presentation of results.
Interpretation: In patients with suspected CHS, lower dose haloperidol (0.05 mg/kg) can be considered as first line supportive therapy in the ED.”